Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Rykindo vs Risperdal Consta in Schizophrenia
NCT02186769Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Jul 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tofacitinib in schizophrenia and schizoaffective disorder (2 arms), sponsored by Luye Pharma Group. Primary endpoint: Maximum Plasma Concentration (Cmax) at 57 days. Started Jul 2014; status: completed.
02
Drugs
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT02186769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02186769.